What question did this study set out to answer?

To update the 2008 U.S. Preventive Services Task Force recommendation on prostate-specific antigen (PSA)-based screening for prostate cancer.

Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement

View Full Paper

Ask AI

Bookmark

Authors

Clinical guideline recommends against PSA-based prostate cancer screening in the general male population, highlighting harms outweigh benefits.

To update the 2008 U.S. Preventive Services Task Force recommendation on prostate-specific antigen (PSA)-based screening for prostate cancer.
The Task Force evaluated updated evidence evaluating the benefits and harms of PSA-based screening for prostate cancer.
Evidence regarding the downstream benefits and harms associated with the treatment of localized prostate cancer was systematically reviewed.
The USPSTF issued a Grade D recommendation, advising against PSA-based screening for prostate cancer across all age groups in the general population.
The guidance excludes diagnostic surveillance and post-treatment monitoring in individuals with an established prostate cancer diagnosis.

Virginia A. Moyer (2012) studied this question.

View Full Paper

Ask AI

Bookmark

Clinical guideline recommends against PSA-based prostate cancer screening in the general male population, highlighting harms outweigh benefits.